GREY:ATBPF - Post by User
Comment by
WalkOverTheStrton May 09, 2021 12:24pm
242 Views
Post# 33161957
RE:ATE.TO Drug Pipeline = $50B plus
RE:ATE.TO Drug Pipeline = $50B plusThe hydrogen sulfide is not a "platform" until it shows success in at least two human studies. The HS2 IP is not a proven platform and therefore the market will give little value to the preclinical pipeline. Antibe could and will strengthen it's negotations once 352 has at a min PH1 positive results. We should all hope Antibe does not delay expanding 352 and / or other preclinicial drugs as the human data needs to be presented / abosrbed by the market. I'd suggest looking at RNAI and specifically Alny and ARWR (going thru this case with their outside the liver drugs ENAC/HIF2 - little credit / value although these drugs could be instrumental / PH1 data out in weeks/months)